Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 401-409

  Khunti, K ^a   Nikolajsen, A ^b   Thorsted, B L ^b   Andersen, M ^c   Davies, M J ^a   Paul, S K ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c DK 1573 Copenhagen V Denmark   (Denmark)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Basal; Glucagon like peptide 1; Glycaemic control; Intensive insulin therapy; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; AGONISTS; BLOOD; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; GENERAL PRACTITIONER; HYPERGLYCEMIA; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; UNITED KINGDOM;

AGED; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PHYSICIANS, PRIMARY CARE; PRACTICE PATTERNS, PHYSICIANS'; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; UNITED KINGDOM;

EID: 84960090337     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12626     Document Type: Article

References (38)

1. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32(Suppl. 2): S151-156.
2. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1): S14-80.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
4. Chatterton H, Younger T, Fischer A, Khunti K; Programme development group. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 2012; 345: e4624.
5. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. Paul S, Thorsted BL, Wolden M, Klein K, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Diabetologia 2013; 56: S534-S535.
8. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80, 000 people. Diabetes Care 2013; 36: 3411-3417.
9. Yam FK, Adams AG, Divine H, Steinke D, Jones MD. Clinical inertia in type 2 diabetes: a retrospective analysis of pharmacist-managed diabetes care vs. usual medical care. Pharmacol Pract 2013; 11: 203-210.
10. Coan KE, Schlinkert AB, Beck BR et al. Clinical inertia during postoperative management of diabetes mellitus: relationship between hyperglycemia and insulin therapy intensification. J Diabetes Sci Technol 2013; 7: 880-887.
11. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
12. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes 2010; 4: 203-207.
13. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007; 24: 1412-1418.
14. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012; 166: 159-170.
15. Mosenzon O, Raz I. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care 2013; 36(Suppl. 2): S212-218.
16. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012; 29: e13-20.
17. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
18. Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
19. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 2009; 8: 9.
20. LaSalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc 2013; 113: 152-162.
21. Khan NF, Harrison S, Rose P. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128-e136.
22. Williams T, Van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
23. Tate AR, Beloff N, Al-Radwan B et al. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J Am Med Inform Assoc 2014; 21: 292-298.
24. de Lusignan S, Sadek N, Mulnier H, Tahir A, Russell-Jones D, Khunti K. Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabet Med 2012; 29: 181-189.
25. Mulnier HE, Seaman HE, Raleigh VS et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia 2006; 49: 2859-2865.
26. National Institute for Health and Care Excellence (NICE). 6.1 drugs used in diabetes 2015 (January). Available from URL: http://www.evidence.nhs.uk/formulary/bnf/current/6-endocrine-system/61-drugs-used-in-diabetes. Accessed 1 October 2015.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
28. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012; 13: 56.
29. Patel N, Stone MA, Chauhan A, Davies MJ, Khunti K. Insulin initiation and management in people with type 2 diabetes in an ethnically diverse population: the healthcare provider perspective. Diabet Med 2012; 29: 1311-1316.
30. Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med 2015; 32: 407-413.
31. Khunti K, Davies MJ, Kalra S. Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab 2013; 15: 690-700.
32. Thong KY, Jose B, Sukumar N et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab 2011; 13: 703-710.
33. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
34. Lee YK, Ng CJ, Lee PY et al. What are the barriers faced by patients using insulin? A qualitative study of Malaysian health care professionals' views. Patient Prefer Adherence 2013; 7: 103-109.
35. Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient 2014; 7: 437-450.
36. Bloomgarden ZT. Glycemic control in diabetes: a tale of three studies. Diabetes Care 2008; 31: 1913-1919.
37. Khunti K, Damci T, Meneghini L, Pan CY, Yale JF; SOLVE Study Group. Study of once daily levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 2012; 14: 654-661.
38. Health and Social Care Information Centre (HSCIC). Quality and outcomes framework. Available from URL: http://www.hscic.gov.uk/qof. Accessed 1 October 2015.